Eculizumab dose tapering should take into account the nonlinearity of its pharmacokinetics.
Olivier Le TillyPhilippe GataultSaida SemlaliRebecca Sberro-SoussanChristophe PassotDominique BertrandCéline DesvignesSophie CaillardGilles PaintaudJean-Michel HalimiDavid TernantPublished in: British journal of clinical pharmacology (2024)
Our study investigates the nonlinear elimination of eculizumab and discusses the importance of accounting for eculizumab target-mediated elimination in therapeutic drug monitoring.
Keyphrases